Since the arrival of Crispr in 2009, gene editing has made its way into labs. Its groundbreaking importance was acknowledged through the 2020 Nobel Prize in Chemistry. Expanding gene editing for medical treatments, Cellectis focuses its 20 years of experience on developing cancer immunotherapies.
Curious to Know More?
Cellectis CEO André Choulika explains the technology of allogenic gene editing they invented in this episode of the podcast "A View On."
Create your
podcast in
minutes
It is Free